XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Activity Related to Stock Options


 

Number of Options

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (Years)

 

 

Aggregate Intrinsic Value

Outstanding, January 1, 2021 

 

3,815,585

 

 

$

5.56

 

 

 

8.9

 

 $

342,551

Granted

 

1,345,136

 

 

 

1.97

 

 

 

 

 

 

21,600

Exercised

 

 

 

 

 

 

 

 

 

 

 —

Cancelled

 

(29,458

)

 

 

5.22

 

 

 

 

 

 

*  

Outstanding, September 30, 2021


5,131,263


 

$

4.62



 

8.2


 $

73,800

Exercisable, September 30, 2021

 

1,988,192

 

 

$

7.67

 

 

 

7.6

 

$

36,000

Summary of Activity Related to Restricted Stock Awards Granted


 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

 

Nonvested, January 1, 2021

  

 

25,645

 

 

$

10.07

 

 

Granted

 

 

165,413

 

 

 

2.41

 

 

Vested

 

 

(149,894

)

 

 

2.82

 

 

Cancelled

 

  

(5,687

)

 

 

6.38

 

 

Nonvested, September 30, 2021

 

 

35,477

 

 

$

2.82

 

 

Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted


 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

Nonvested, January 1, 2021

 

 

1,014,123

 

 

$

1.50

 

Granted

 

 

438,316

 

 

 

2.07

 

Vested

 

 

(329,198

)

 

 

1.67

 

Cancelled

 

 

(5,354

)

 

 

1.97

 

Nonvested, September 30, 2021

 

 

1,117,887

 

 

$

1.67

 

Schedule of Recognized Stock Compensation for Equity Awards


 



Three months ended September 30,

Nine months ended September 30,


 


2021


2020


2021

 

 

2020


Selling, general and administrative


$ 658,314

$ 541,757

$

2,171,122

 

 

$

1,789,122

 

Research and development



87,222


179,664

 

314,710

 

 

 

649,485

 

Cost of goods sold



14,901


21,507

 

54,761

 

 

 

51,944

 

Total expense 
$ 760,437

$ 742,928

$

2,540,593

 

 

$ 2,490,551

 

Summary of Weighted Average Assumptions Used in Valuing Plans



Nine months ended September 30,


2021


2020

Fair value at grant date

$

1.33

 

$ 0.98

Expected volatility

80.2


142.1
 

Risk-free interest rate

0.7


0.7 %

Expected holding period, in years

6.0

 


6.1

Dividend yield

 


%